FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1009-1017 September 4, 2008 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Healey, J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Patients with heart failure who receive an implantable cardioverter–defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) may later receive therapeutic shocks from the ICD. Information about long-term prognosis after ICD therapy in such patients is limited.

Methods Of 829 patients with heart failure who were randomly assigned to ICD therapy, we implanted the ICD in 811. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate. All other ICD shocks were considered to be inappropriate.

Results Over a median follow-up period of 45.5 months, 269 patients (33.2%) received at least one ICD shock, with 128 patients receiving only appropriate shocks, 87 receiving only inappropriate shocks, and 54 receiving both types of shock. In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes (hazard ratio, 5.68; 95% confidence interval [CI], 3.97 to 8.12; P<0.001). An inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death (hazard ratio, 1.98; 95% CI, 1.29 to 3.05; P=0.002). For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated (hazard ratio, 2.99; 95% CI, 2.04 to 4.37; P<0.001). The most common cause of death among patients who received any ICD shock was progressive heart failure.

Conclusions Among patients with heart failure in whom an ICD is implanted for primary prevention, those who receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks.

Source Information

From the University of Washington (J.E.P., D.P.F., G.H.B.); and the Seattle Institute for Cardiac Research (G.W.J., J.A., G.H.B.) — both in Seattle; Duke Clinical Research Institute, Durham, NC (A.S.H., D.B.M., K.L.L.); University of Pennsylvania, Philadelphia (D.J.C., F.E.M.); Portland Veterans Affairs Medical Center and Oregon Health Sciences University, Portland (M.H.R.); Oregon Cardiology Associates, Eugene (R.K.R.); University Hospital, London, ON, Canada (R.Y.); Johns Hopkins University, Baltimore (T.G.); Institut de Cardiologie de Montréal, Université de Montréal, Montreal (M.T.); Loyola University Medical Center, Maywood, IL (D.J.W.); and the Mayo Clinic, Rochester, MN (D.L.P.).

Address reprint requests to Dr. Poole at the Division of Cardiology, University of Washington School of Medicine, 1959 NE Pacific St., Box 356422, Seattle, WA 98195-6422, or at jpoole{at}u.washington.edu.

Full Text of this Article

Related Letters:

Defibrillators in Heart Failure and Quality of Life
Matlock D. D., Telerant R. M., Boyer N., Kansagara D., Passman R., Kadish A., Sears S., Mark D. B.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:187-189, Jan 8, 2009. Correspondence

This article has been cited by other articles:

• Mishkin, J. D., Saxonhouse, S. J., Woo, G. W., Burkart, T. A., Miles, W. M., Conti, J. B., Schofield, R. S., Sears, S. F., Aranda, J. M. Jr (2009). Appropriate Evaluation and Treatment of Heart Failure Patients After Implantable Cardioverter-Defibrillator Discharge Time to Go Beyond the Initial Shock.. J Am Coll Cardiol 54: 1993-2000 [Abstract] [Full Text]  
• Goldberger, J. J., Passman, R. (2009). Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction The Results Are Not Shocking.. J Am Coll Cardiol 54: 2001-2005 [Abstract] [Full Text]  
• Gasparini, M., Menozzi, C., Proclemer, A., Landolina, M., Iacopino, S., Carboni, A., Lombardo, E., Regoli, F., Biffi, M., Burrone, V., Denaro, A., Boriani, G. (2009). A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J 30: 2758-2767 [Abstract] [Full Text]  
• Steinbeck, G., Andresen, D., Seidl, K., Brachmann, J., Hoffmann, E., Wojciechowski, D., Kornacewicz-Jach, Z., Sredniawa, B., Lupkovics, G., Hofgartner, F., Lubinski, A., Rosenqvist, M., Habets, A., Wegscheider, K., Senges, J., the IRIS Investigators, (2009). Defibrillator Implantation Early after Myocardial Infarction. NEJM 361: 1427-1436 [Abstract] [Full Text]  
• Garber, A. M., Hlatky, M. A. (2009). The Confirmatory Trial in Comparative-Effectiveness Research. NEJM 361: 1498-1499 [Full Text]  
• Tung, R., Swerdlow, C. D. (2009). Refining Patient Selection for Primary Prevention Implantable Cardioverter-Defibrillator Therapy: Reeling in a Net Cast Too Widely. Circulation 120: 825-827 [Full Text]  
• Brignole, M. (2009). Are complications of implantable defibrillators under-estimated and benefits over-estimated?. Europace 11: 1129-1133 [Full Text]  
• Myerburg, R. J., Reddy, V., Castellanos, A. (2009). Indications for implantable cardioverter-defibrillators based on evidence and judgment.. J Am Coll Cardiol 54: 747-763 [Abstract] [Full Text]  
• Marcus, G. M., Keung, E., Scheinman, M. M. (2009). The year in review of clinical cardiac electrophysiology.. J Am Coll Cardiol 54: 777-787 [Full Text]  
• Tereshchenko, L. G., Faddis, M. N., Fetics, B. J., Zelik, K. E., Efimov, I. R., Berger, R. D. (2009). Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression.. J Am Coll Cardiol 54: 822-828 [Abstract] [Full Text]  
• Shepard, R. K., Ellenbogen, K. A. (2009). Predicting outcome after implantable cardioverter-defibrillator therapy a new piece to the puzzle?. J Am Coll Cardiol 54: 829-831 [Full Text]  
• Israel, C. W. (2009). Do some implant too many defibrillators or others too few?. Europace 11: 982-984 [Full Text]  
• Task force members, , Vijgen, J., Botto, G., Camm, J., Hoijer, C.-J., Jung, W., Le Heuzey, J.-Y., Lubinski, A., Norekval, T. M., Santomauro, M., Schalij, M., Schmid, J.-P., Vardas, P. (2009). Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 11: 1097-1107 [Abstract] [Full Text]  
• Blendea, D, Blendea, M, Banker, J, McPherson, C A (2009). Troponin T elevation after implanted defibrillator discharge predicts survival. Heart 95: 1153-1158 [Abstract] [Full Text]  
• Cevik, C., Perez-Verdia, A., Nugent, K. (2009). Implantable cardioverter defibrillators and their role in heart failure progression. Europace 11: 710-715 [Abstract] [Full Text]  
• Aliot, E. M., Stevenson, W. G., Almendral-Garrote, J. M., Bogun, F., Calkins, C. H., Delacretaz, E., Bella, P. D., Hindricks, G., Jais, P., Josephson, M. E., Kautzner, J., Kay, G. N., Kuck, K.-H., Lerman, B. B., Marchlinski, F., Reddy, V., Schalij, M.-J., Schilling, R., Soejima, K., Wilber, D. (2009). EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace 11: 771-817 [Full Text]  
• Meine, M., Smith, T., Hauer, R. N.W. (2009). The economical challenge in the treatment of chronic heart failure: is primary prophylactic ICD therapy cost-effective in Europe?. Europace 11: 689-691 [Full Text]  
• Matlock, D. D., Telerant, R. M., Boyer, N., Kansagara, D., Passman, R., Kadish, A., Sears, S., Mark, D. B. (2009). Defibrillators in Heart Failure and Quality of Life. NEJM 360: 187-189 [Full Text]  
• Rosenbaum, D. S. (2008). T-Wave Alternans in the Sudden Cardiac Death in Heart Failure Trial Population: Signal or Noise?. Circulation 118: 2015-2018 [Full Text]  
• Healey, J., Connolly, S. (2008). Life and Death after ICD Implantation. NEJM 359: 1058-1059 [Full Text]  
• (2008). QOL and Mortality Among Heart Failure Patients with Implantable Cardioverter-Defibrillators. JWatch General 2008: 4-4 [Full Text]  
• (2008). Beware of Implantable Cardioverter-Defibrillator Shocks!. Journal Watch Cardiology 2008: 2-2 [Full Text]